Professor Gordon Jayson is a Consultant Medical Oncologist based at The Christie NHS Foundation Trust in Manchester.
Professor Jayson has developed new treatments for cancer, in particular ovarian cancer, focusing principally on drugs that block blood vessel formation to starve tumours of oxygen and nutrients. Professor Jayson provides a supra-regional service for patients with new diagnoses and previously treated ovarian cancer.
Having trained in medicine at Oxford University, Professor Jayson trained in oncology and undertook a PhD in molecular biochemistry and angiogenesis in Manchester and the Christie Hospital.
Following his PhD, Professor Jayson has conducted post-doctoral research that aims to translate the new data from heparan sulfate biology into the clinic. His current programme of work is directed at the laboratory development of novel oligosaccharides as anti-angiogenic agents and the early and late clinical trial evaluation of this class of drugs. The latter programme aims to identify serological and imaging based biomarkers that will identify the patients who are most likely to benefit from this these agents and which will be used to underpin the development of combination regimens of biological agents. This work is largely focused on ovarian cancer, the disease that Professor Jayson looks after in Christie Hospital.